Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on IVERIC bio (ISEE – Research Report), Sensus Healthcare (SRTS – Research Report) and Immuneering (IMRX – Research Report).
IVERIC bio (ISEE)
B.Riley Financial analyst Yuan Zhi reiterated a Hold rating on IVERIC bio today and set a price target of $40.00. The company’s shares closed last Thursday at $37.37, close to its 52-week high of $38.25.
According to TipRanks.com, Zhi is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for IVERIC bio with a $37.30 average price target, which is a 0.1% upside from current levels. In a report issued on May 1, Guggenheim also downgraded the stock to Hold.
See Insiders’ Hot Stocks on TipRanks >>
Sensus Healthcare (SRTS)
In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Sensus Healthcare. The company’s shares closed last Thursday at $2.72, close to its 52-week low of $2.29.
According to TipRanks.com, Vendetti is a 1-star analyst with an average return of
Currently, the analyst consensus on Sensus Healthcare is a Strong Buy with an average price target of $8.33, implying a 212.0% upside from current levels. In a report released yesterday, Alliance Global Partners also maintained a Buy rating on the stock with a $7.00 price target.
Immuneering (IMRX)
In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Immuneering, with a price target of $22.00. The company’s shares closed last Thursday at $8.03.
According to TipRanks.com, Livshits is a 5-star analyst with an average return of
Currently, the analyst consensus on Immuneering is a Strong Buy with an average price target of $19.40, representing a 123.5% upside. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $20.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ISEE:
- Biotech Alert: Searches spiking for these stocks today
- Iveric bio downgraded to Neutral from Buy at UBS
- Iveric bio downgraded to Neutral from Buy at H.C. Wainwright
- Iveric bio downgraded to Neutral from Outperform at Credit Suisse
- Guggenheim downgrades Iveric bio after deal, doesn’t expect other bidders
